Utjecaj akarboze na katalitičke aktivnosti alanin aminotransferaze i aspartat aminotransferaze u jetri kontrolnih i dijabetičnih CBA miševa by ROBERTA PETLEVSKI et al.
Acarbose, a complex oligosaccharide that acts by competitive and reversible inhibi-
tion of small intestine brush-border a-D-glucosidases thereby delaying absorption of
carbohydrates in the gut, is increasingly used for the treatment of diabetes type II (1).
Additional findings indicate that a-D-glucosidase inhibitors also act specifically on the
entry of free glucose into the enterocytes (2). Due to these effects, treatment with acarbose
results in reduced postprandial blood glucose levels, and reduced postprandial hyper-
insulinemia (3).
Delayed carbohydrate digestion increases the amount of fermentable carbohydrate
in the bowel, which does not appear to cause calorie loss because of the metabolism to
other absorbable nutrients by colonic microflora (4).
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The purpose of this study was to examine the short-term
effects of diet containing 0.1% (m/m) of acarbose in stan-
dard laboratory chow on specific liver enzyme activities:
alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) in control and diabetic CBA mice. Diabetes
was induced by intravenous injection of alloxan mono-
hydrate in a dose of 75 mg kg–1 mouse body mass seven
days before the treatment with acarbose. There were four
groups of CBA mice in the experiment: control (C) mice
(n = 6) and diabetic (D) mice (n = 8) fed standard chow;
control (C/A-100) mice (n = 8) and diabetic (D/A-100)
mice (n = 8) fed standard chow containing 0.1% acarbose.
Diabetes induced a decrease of the ALT catalytic activi-
ties to 69.6% of the control value. A similar level of de-
creased ALT catalytic activity was detected in the liver of
control and diabetic mice fed chow containing 0.1% acar-
bose. No changes in the specific and total activities of AST
in the liver of experimental groups were observed.
Keywords: acarbose, alanine aminotransferase, aspartate
aminotransferase, diabetes
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Ahr et al. (5) studied absorption, disposition, metabolism and excretion of acarbose
following a single administration of 14C-labelled compound to rats and dogs via differ-
ent routes (intravenous, oral, intraduodenal) in the dose range of 2–200 mg kg–1 as well
to man in a single oral dose of 200 mg. After oral administration 14C-acarbose was very
poorly adsorbed (1–2% of the dose in rats and man and 4% in dogs). Additionally, up to
35% of the radioactivity of 14C-acarbose was absorbed after degradation by digestive en-
zymes and/or intestinal microorganisms.
Since acarbose is minimally absorbed in unchanged form after oral administration,
the drug is widely believed to be safe, with only flatulence as a commonly reported
complaint, and rarely a severe gastrointestinal disturbance such as ileus (6, 7).
Contrary to this opinion, acarbose has been incriminated in several reports of dose-
-related hepatotoxicity and higher serum alanine aminotransferase (ALT) activity with
normal aspartate aminotransferase (AST) activities in humans (8, 9). This effect could be
induced by reabsorbed acarbose or its metabolites on the structure and metabolic activ-
ity of the liver (10). Therefore acarbose has been put on the list of drugs which may in-
duce acute hepatitis (11).
In our previous study, we studied short-term effects of 0.075, 0.1 and 0.15% (m/m)
acarbose mixed in standard chow on specific intestinal disaccharidase activities and on
hyperglycaemia in diabetic CBA mice (12). We found that feeding with 0.1 or 0.15%
acarbose in standard laboratory chow for seven days caused a statistically significant de-
crease in specific maltase and sucrase activities in duodenum, jejunum and ileum while
antihyperglycaemic effect was observed only in the group of diabetic mice fed 0.12 ac-
arbose.
For this reason, we selected this antihyperglycaemically effective dose to test the
possible short-term effect of acarbose mixed in standard laboratory chow on the ALT
and AST activities in liver of control and diabetic CBA mice.
EXPERIMENTAL
Animals
Three-month IRB bred, male CBA mice, body mass 25–30 g, were used in the study.
The mice were housed in metabolic cages on a 12-h light/dark cycle at a temperature of
22–24 °C. All mice were fed ad libitum with standard laboratory chow (Pliva, Croatia)
and had free access to water. Diabetes was induced by intravenous injection of alloxan
monohydrate (Sigma, USA) in Hank’s solution (pH 7.0) in a dose of 75 mg kg–1 body
mass seven days before the treatment with acarbose. Seven days after alloxan injection,
blood was collected from the tail vein of control and diabetic mice for measuring glu-
cose. Diabetic mice with blood glucose beyond 20 mmol L–1 were selected for acarbose
diet.
There were four groups of CBAmice in the experiment: control (C) mice (n = 6) and
diabetic (D) mice (n = 8) fed on standard chow; control (C/A-100) mice (n = 8) and dia-
betic (D/A-100) mice (n = 8) fed a mixture containing 100 mg acarbose per 100 g of stan-
dard chow. They were fed this diet ad libitum for seven days. Chows with mixed acarbose
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were prepared daily. Body mass was measured before and after seven days of feeding,
while food and water intake were measured daily. Blood was collected again from the
tail vein before mice were sacrificed under ether anaesthesia, between 9:00 and 10:00 h,
without fasting.
This study was approved by the Research Ethics Committee of the Ru|er Bo{kovi}
Institute, Zagreb.
Liver homogenates
Liver was immediately excised, washed in ice-cold saline and then blotted on tissue
paper. Liver tissues were homogenized (100 g L–1) in cold 0.14 mol L–1 KCl using a Tef-
lon homogenizator (Measuring & Scientific Equipment, UK). Homogenates were centri-
fuged at 12000 g for 30 minutes in a Mistral 2 L-refrigerated centrifuge (Measuring &
Scientific Equipment). Supernatants were stored at –20 °C until analysis.
Methods
ALT and AST activities were determined using IFCC recommended UV methods
(HD dijagnostika, Croatia) on a Technicon RA-1000 biochemical analyser (Bayer, Italy).
Protein concentration was determined by the method of Lowry et al. (13) using bovine
serum albumin as standard. Blood glucose concentrations was determined by the glu-
cose oxidase method (HD dijagnostika).
Statistics
Data are shown as means ± standard deviation. They were compared using the
ANOVA one-way test of variance. The value of p < 0.05 was considered the significance
level. SigmaStat program for Windows, version 2.0 (Jandel Corporation, USA), was used
for statistical analysis.
RESULTS AND DISCUSSION
In order to test the effect of feeding, body masses of experimental mice were mea-
sured before and after seven days of feeding with standard chow or with 0.1% acarbose
in standard chow. No significant differences in body mass between the groups were
found, either before or after the treatment. Mean blood glucose concentration decreased
significantly to 71.6% (p < 0.05) in the group of diabetic mice (D/A-100) fed 0.1% acar-
bose for seven days compared to untreated diabetic mice (D) (Table I).
No differences between the groups were found in the content of total proteins in the
liver (Table II). Significantly lowered liver masses were found in control mice (C/A-100)
(88%, p < 0.05) and diabetic mice (D/A-100) (89%, p < 0.05) fed acarbose compared to
control mice (C) fed standard chow. The same result was recorded for diabetic mice
(D/A-100) (89%, p < 0.05) fed acarbose in comparison with diabetic mice (D) on stan-
dard diet. Due to the fact that the diabetic mice had lower body mass at the beginning of
the treatment with acarbose, the ratio of the liver mass to body mass is better indication
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of the changes in the liver structure and possible metabolic activity. In our study, ratio of
liver mass to body mass was significantly higher in diabetic mice on standard diet (D)
(134%, p < 0.05) compared to control mice on standard diet (C). Ratio of liver mass to
body mass decreased significantly in the group of diabetic mice (D/A-100) fed acarbose
for seven days.
In our study, this ratio increased in diabetic mice (D), probably due to the storage of
many lipid granules in the hepatocytes, as observed by Degirmenci et al. (14), who in-
vestigated the effect of acarbose on the liver ultra-structure in streptozotocin-induced di-
abetes in neonatal rats. They also found lysosomal bodies in the hepatocytes of diabetic
rats treated with acarbose. This is in agreement with the results of Lembcke et al. (15),
who additionally found that the effect of lysosomal storage of glycogen depends on the
type of alpha-glucosidase inhibitors (emiglitate > miglitol > acarbose).
Acarbose is minimally absorbed in an unchanged form after oral administration
and the mechanism of acarbose-induced liver injury is still unknown.
Table III presents specific and total activities of ALT and AST in the liver of experi-
mental groups. Fourteen days after induction of diabetes, both specific and total ALT ac-
tivities were significantly lowered in the diabetic mice on standard diet (D) (68.6 and
50%, respectively, p < 0.05) compared to the control mice on standard diet (C). Similar
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Table I. Body mass and blood glucose of CBA micea
Group n
Body mass (g) Blood glucose
(mmol L–1)Before treatment After treatment
Control mice (C) 6 29.3 ± 2.9 30.0 ± 3.2 8.76 ± 0.86
Control mice on acarbose (C/A-100) 8 28.7 ± 2.8 28.1 ± 2.6 7.50 ± 1.21
Diabetic mice (D) 8 24.0 ± 2.3 22.7 ± 0.4 24.45 ± 3.46b
Diabetic mice on acarbose (D/A-100) 8 25.1 ± 3.6 25.5 ± 2.7 17.50 ± 5.75b, c
a Data are presented as mean ± standard deviation.
b Significantly different from control group (C) (p < 0.05).
c Significantly different from diabetic group (D) (p < 0.05).
Table II. Liver mass and content of proteins in the liver of CBA micea





Control mice (C) 6 1.52 ± 0.18 0.050 ± 0.002 0.307 ± 0.044
Control mice on acarbose (C/A-100) 8 1.34 ± 0.09b 0.048 ± 0.005 0.283 ± 0.031
Diabetic mice (D) 8 1.53 ± 0.11 0.067 ± 0.005b 0.304 ± 0.091
Diabetic mice on acarbose (D/A-100) 8 1.36 ± 0.17b,c 0.054 ± 0.008c 0.296 ± 0.066
a Data are presented as mean ± standard deviation.
b Significantly different from control group (C) (p < 0.05).
c Significantly different from diabetic group (D) (p < 0.05).
levels of decreased specific and total ALT activities were observed in the liver of control
(C/A-100) and diabetic (D/A-100) mice fed acarbose for seven days. No changes in spe-
cific and total activities of AST in the liver of experimental groups were observed. The
difference between the ALT and AST activity profiles could be explained by the slightly
increased permeability of plasma membrane, probably caused by acarbose alone, and
the loss of ALT as a cytoplasmatic enzyme from the cells. Those effects are probably con-
sequence of markadly higher amounts of acarbose applied in the current experiment
(111.9 mg kg–1 b. m.) compared to the usual amount of acarbose administered to human
patients (4 mg kg–1 b. m.). Another explanation of the metabolic and structural differ-
ences of the liver lobules and the distribution of acarbose or its metabolites in the liver
could be also taken into account. ALT is a cytosolic, periportally prevailing enzyme
while AST is a cytosolic as well as mitochondrial perivenously located enzyme (16). This
explanation is supported by our results on the same experimental model, where we
proved decreased glucose-6-phosphatase activity, another enzyme predominantly lo-
cated in the periportal part of the liver (17, 18). The use of acarbose in the usual doses
might be presummed safe in the treatment of diabetes mellitus.
CONCLUSIONS
Decreased ALT catalytic activity was detected in the liver of control and diabetic
mice fed chow containing 0.1% acarbose. No changes in specific and total activities of
AST in the liver of experimental groups were observed, indicating possibly slightly in-
creased permeability of liver cells plasma membrane. A better insight into the effect of
on ALT and AST activity profiles could be gained by higher amounts of acarbose and by
monitoring its metabolites in the liver.
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(U per total liver)
Control mice (C) 6 372 ± 26 114 ± 14 889 ± 71 272 ± 36
Control mice on
acarbose (C/A-100)
8 241 ± 83b 68 ± 21b 740 ± 127 210 ± 41
Diabetic mice (D) 8 259 ± 108b 57 ± 23b 1146 ± 520 266 ± 153
Diabetic mice on
acarbose (D/A-100)
8 234 ± 76b 67 ± 21b 944 ± 320 271 ± 85
a Data are presented as mean ± standard deviation.
b Significantly different from control group (C) (p < 0.05).
c Significantly different from diabetic group (D) (p < 0.05).
REFERENCES
1. J. A. Balfour and D. McTravish, Acarbose: An update of its pharmacology and therapeutic use
in diabetes mellitus, Drugs 46 (1993) 1025–1054.
2. A. J. Hirsh, S. Y. Yao, J. D. Young and C. I. Cheeseman, Inhibition of glucose absorption in the
rat jejunum: a novel alpha-D-glucosidase inhibitors, Gastroenterology 113 (1997) 205–211.
3. M. Hanefeld, The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus,
J. Diabetes Complicat. 12 (1998) 228–237.
4. S. Fischer, M. Hanefeld, M. Spengler, K. Boehme and T. Temelkova-Kurktschiev, European study
on dose-response relationship of acarbose as a first-line drug in non-insulin dependent diabetes
mellitus: efficacy and safety of low and high doses, Acta Diabetol. 35 (1998) 34–40.
5. H. J. Ahr, M. Boberg, H. P. Krause, W. Maul, F. O. Muller, H. J. Ploschke, H. Weber and C. Wunsche,
Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and ex-
cretion after a single administration of 14C-acarbose to rats, dog and man, Arzneimittel-Forsch.
39 (1989) 1254–1260.
6. P. Hollander, Safety profile of acarbose, an alpha glucosidase inhibitor, Drugs 44 (Suppl. 2)
(1992) 47–53.
7. M. Odawara, C. Bannai, T. Saitoh, Y. Kawakarni and K. Yamahita, Potentially lethal ileus associ-
ated with acarbose treatment for NIDDM, Diabetes Care 20 (1997) 1210–1211.
8. R. J. Andrade, M. Lucena, J. L. Vega, M. Torres, F. J. Salmeron, V. Bellot, M. D. Garcia-Escano
and P. Moreno, Acarbose-associated hepatotoxicity, Diabetes Care 21 (1998) 2029–2030.
9. J. De La Vega, M. Crepso, J. M. Escudero, L. Sanchez and L. L. Rivas, Acarbose-induced acute
hepatitis. Report of two events in the same patient, Gastroenterol. Hepatol. 23 (2000) 282–284.
10. M. Boberg, J. Kurz, H. J. Ploschke, P. Schmitt, H. Scholl, M. Schuller and C. Wunsche, Isolation
and structural elucidation of biotransformation products from acarbose, Arzneimittel-Forsch. 40
(1990) 555–563.
11. S. Chitturi and J. George, Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflamma-
tory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psy-
chotropic drugs, Semin. Liver Dis. 22 (2002) 169–183.
12. D. Jureti}, [. Bernik, Lj. ^op, M. Had`ija, R. Petlevski and J. Luka~-Bajalo, Short-term effect of
acarbose on specific intestinal disaccharidase activities and hyperglycaemia in CBA diabetic
mice, J. Anim. Physiol. Anim. Nutr. 87 (2003) 263–268.
13. O. H. Lowry, N. Rosebrough, A. L. Farr and R. J. Randall, Protein measurement with the Folin
phenol reagens, J. Biol. Chem. 193 (1951) 265–270.
14. I. Degirmenchi, S. Kalender, M. C. Ustuner, Y. Kalender, H. V. Gunes, N. Unal and A. Basaran,
The effects of acarbose and Rumex patientia on liver ultrastructure in streptozotocin-induced di-
abetic (type II) rats, Drugs Exp. Clin. Res. 28 (2002) 229–234.
15. B. Lembcke, R. Lamberts, J. Wohler and W. Creutzfeldt, Lysosomal storage of glycogen as a se-
quel of alpha-glucosidase inhibition by the absorbed deoxynojirimycin derivate emiglitate (BAYo
1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe’s disease (glyco-
genosis type II), Res. Exp. Med. 191 (1991) 389–404.
16. E. Schmidt and F. W. Schmidt, Enzyme release, J. Clin. Chem. Clin. Biochem. 25 (1987) 525–540.
17. R. Petlevski, D. Jureti}, Lj. Mayer, M. Had`ija, M. Slijep~evi} and J. Luka~-Bajalo, Effect of ac-
arbose on glucose-6-phosphatase in liver of CBA diabetic mice, Period. Biol. 104 (2002) 73–75.
18. J. Radziuk and S. Pye, Hepatic glucose uptake, gluconeogenesis and the regulation of glycogen
synthesis, Diabetes Metab. Res. Rev. 17 (2001) 250–272.
92
R. Petlevski et al.: Effect of acarbose on alanine aminotransferase and aspartate aminotransferase activities in the liver of control and
diabetic CBA mice, Acta Pharm. 56 (2006) 87–93.
S A @ E T A K
Utjecaj akarboze na kataliti~ke aktivnosti alanin aminotransferaze i aspartat
aminotransferaze u jetri kontrolnih i dijabeti~nih CBA mi{eva
ROBERTA PETLEVSKI, MIRKO HAD@IJA, JANA LUKA^ BAJALO i DUBRAVKA JURETI]
Svrha ovog rada bila je ispitati kratkotrajni u~inak 0.1% (m/m) akarboze u suhoj
hrani na kataliti~ku koncentraciju specifi~nih jetrenih enzima: alanin aminotransferaze
(ALT) i aspartat aminotransferaze (AST) u jetri kontrolnih i dijabeti~nih CBAmi{eva. Di-
jabetes je bio izazvan i.v. injekcijom aloksan-monohidrata u dozi od 75 mg kg–1 tjelesne
mase mi{a sedam dana prije po~etka ishrane s akarbozom. U pokusu su ispitane ~etiri
skupine CBA mi{eva: kontrolna (C) (n = 6) i dijabeti~na (D) (n = 8) skupina bile su se-
dam dana na standardnoj ishrani, te kontrolna (C/A-100) (n = 8) i dijabeti~na (D/A-100)
(n = 8) skupina koje su hranjene 0.1% akarbozom umije{anom u standardnu hranu. U
skupini D kataliti~ka koncentracija ALT-a bila je zna~ajno sni`ena u usporedbi s kon-
trolnom skupinom C. Sli~an pad kataliti~ke koncentracije ALT-a zabilje`en je i u jetri
kontrolnih i dijabeti~nih mi{eva hranjenih suhom hranom u koju je bila umije{ena akar-
boza (0.1%). U ispitanim skupinama nisu zabilje`ene promjene u specifi~noj i ukupnoj
aktivnosti AST-a.
Klju~ne rije~i: akarboza, alanin aminotransferaze, aspartat aminotransferaze, dijabetes
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